Dr. Diane Young, M.D., has been Chief Medical Officer and Vice President at GTX Inc. since July 13, 2015. Dr. Young is a board-certified medical oncologist with 25 years of industry clinical development experience. She served as Vice President and Global Head of Clinical Development -Oncology of Novartis Pharmaceuticals Corporation. Prior to her employment with Novartis, she spent 10 years with Johnson and Johnson, where she served as Vice President of Global Development at R. W. Johnson Pharmaceutical Research Institute (now Johnson and Johnson Research and Development). At Novartis, Dr. Young held senior leadership positions involved with the development, regulatory approval and medical affairs activities for several oncology products, including Glivec, Zometa, Femara, Sandostatin, Tasigna, Jakavi and Afinitor. Dr. Young received her Medical Degree from the Harvard Medical School, followed by an internship and residency at Johns Hopkins Hospital and Vanderbilt University Hospital. Thereafter, she served as an oncology fellow at the Dana-Farber Cancer Institute. She earned an A.B. in Biochemical Sciences (Magna Cum Laude) from Harvard University.